Tubule-Derived GDF15 Limits Renal Transplant Injury by Reprogramming Macrophage Responses.
Summary
Human allograft transcriptomics and murine transplantation models identify tubule-derived GDF15 as a protective mediator that limits transplant injury by promoting M2 macrophage polarization. Urinary GDF15 correlates with graft dysfunction, and recombinant GDF15 mitigates injury, implicating ATF4-GDF15 signaling as a therapeutic axis.
Key Findings
- GDF15 is upregulated in renal tubular epithelial cells of human allografts, especially in DGF cases; urinary GDF15 correlates with serum creatinine.
- GDF15 deficiency exacerbates tubular injury and inflammation in murine syngeneic/allogeneic transplant models, while recombinant GDF15 is protective.
- ATF4 regulates GDF15 under renal stress; macrophage depletion confirms macrophage-mediated inflammation drives injury in GDF15-deficient grafts.
Clinical Implications
Urinary GDF15 could aid in early identification of grafts at risk for DGF, and recombinant GDF15 or pathway agonism may be explored as peri-transplant immunometabolic therapies to improve outcomes.
Why It Matters
This work uncovers a tubule–macrophage cross-talk mechanism with direct translational relevance, nominating GDF15 as both a biomarker and a therapeutic candidate to reduce IRI and DGF after kidney transplantation.
Limitations
- Human cohort size and external validation details are not specified in the abstract.
- Translational gaps remain regarding dosing, timing, and safety of recombinant GDF15 in humans.
Future Directions
Prospective studies validating urinary GDF15 as a DGF biomarker, dose-finding and safety trials of recombinant GDF15, and exploration of macrophage-targeted adjuncts in peri-transplant care.
Study Information
- Study Type
- Cohort
- Research Domain
- Pathophysiology
- Evidence Level
- III - Nonrandomized observational human data integrated with mechanistic animal experiments
- Study Design
- OTHER